Genosco

Founded in 2008, Genosco is an early clinical-stage biotech company pursuing discovery and development of novel small-molecule drugs to treat patients with unmet medical needs. We utilize a highly targeted approach with expertise in selective kinase inhibitors. We have discovered several master scaffolds selectively inhibiting protein kinases, which are enzymes that transfer phosphate groups to proteins and are key players in virtually all signal pathways. There are approximately 518 kinases encoded in the human genome and many of them are implicated in human diseases. Our Drug Discovery Group is led by an interdisciplinary team of scientists with expertise in medicinal chemistry, structural & computational drug discovery design, cell biology, pharmacology, and drug metabolism.